Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) announced that, further to its press release dated August 12, 2019 , the British Columbia Securities Commission and the Ontario Securities
View HTML
Toggle Summary Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (“Novelion” or the “Company”), announced that it has
View HTML
Toggle Summary Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition
VANCOUVER, British Columbia , July 16, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on July 16, 2019 , the Supreme Court
View HTML
Toggle Summary Novelion Therapeutics Receives Delisting Notifications
VANCOUVER, British Columbia , July 05, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, announced that on July 3, 2019 , the Company received a written
View HTML
Toggle Summary Novelion Therapeutics Responds to Whitefort Capital Petition
VANCOUVER, British Columbia , June 24, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on June 20, 2019 , Whitefort Capital
View HTML
Toggle Summary Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
Transaction is result of comprehensive capital structure and strategic review conducted independently by both Novelion’s and Aegerion’s Boards of Directors Aegerion will continue to make available to patients its two approved therapies, JUXTAPID ® and MYALEPT ® Novelion to receive approximately 10%
View HTML
Toggle Summary Novelion Therapeutics Reports First Quarter 2019 Financial Results
Company reiterates 2019 guidance of total net revenues between $160.0 and $175.0 million, including approximately $30.0 million of licensing revenues VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , May 07, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.
View HTML
Toggle Summary Novelion Therapeutics Observes World Lipodystrophy Day
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , March 31, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, in association with its subsidiary Aegerion
View HTML
Toggle Summary Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Company achieves FY 2018 total net revenues of $130.4 million   FY 2018 operating expenses reduced by $27.2 million , or 18.4% VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , March 14, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to
View HTML
Toggle Summary Novelion Therapeutics Observes Rare Disease Day
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to
View HTML